Bristol Myers: positive data in psoriatic arthritis

(CercleFinance.com) - Bristol Myers Squibb reports positive results from POETYK PsA-1 and POETYK PsA-2, the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.


After 16 weeks of treatment, both trials met their primary endpoints, with a significantly higher proportion of patients achieving an ACR20 response (at least 20% improvement in disease signs and symptoms) compared to placebo.

In addition, the trials met important secondary endpoints of psoriatic arthritis activity at week 16, and the overall safety profile of Sotyktu was consistent with that established in previous clinical trials.

These are the first Phase 3 clinical trial results for Sotyktu in a rheumatic condition. The product is approved in many countries around the world for the treatment of adults with moderate to severe plaque psoriasis.

Copyright (c) 2024 CercleFinance.com. All rights reserved.